fbpx Skip to main content
Home / Connect / Visgenx

Where Vision Meets Venture Capital

Visgenx is bringing clarity to AMD treatment and working toward therapies that can help millions around the world. With Biocom’s member benefits, they’re able to go further, faster.

Visgenx is developing therapies to address Age-Related Macular Degeneration (AMD), a disease that has no approved treatments but impacts nearly 200 million people worldwide.

Visgenx founder, Santosh Vetticaden, has been an active part of the Biocom capital development community. He understood the value of membership for Visgenx and the exposure it brought to their research.

Visgenx uses Biocom’s member benefits to connect with industry leaders, pitch their vision to potential partners, and leverage support as they continue to develop therapies that will impact millions worldwide.

Visgenx is continuing to develop their pipeline of treatments, and their membership with Biocom means continued connection to others that support their vision for a world without AMD.

Biocom connects vision
to venture capital for California’s
life science industry.

Get connected.
Join Biocom’s community of life science companies that make an impact every day.

Get Connected

Our members’ success is what drives us.

Discover more members’ stories of connection.

Read More

Find out how Biocom connects innovation to investment for Navega and other California life science companies.

Read More

Find out how Biocom connects science and the supply chain for Argonaut and other California life science companies.

Read More

Find out how Biocom connects technology to biology for Cardea and other California life science companies.

Choose your news

Subscribe to Biocom newsletters tailored to yours interests.